Here are links to scientific magazines on-line with articles that directly relate to our work on a therapeutic vaccines for autoimmune diseases
Complementary peptide vaccine in Myasthenia Gravis (MG).
Possible Therapeutic Vaccines for Canine Myasthenia Gravis: Implication for the Human Disease and Associated Fatigue
Galin, F. Shawn , Cheryl L. Chrisman, James R. Cook Jr., Likang Xu, Patricia L. Jackson, Brett D. Noerager, Nathaniel M. Weathington and J. Edwin Blalock
Brain, Behavior, and Immunity, Volume 21, Issue 3, March 2007, Pages 323-331
http://dx.doi.org/10.1016/j.bbi.2006.10.001
Rational design of peptide vaccines for autoimmune disease: harnessing molecular recognition to fix a broken network
Weathington, Nathaniel M. and J. Edwin Blalock
Expert Review of Vaccines, Vol. 2, No. 1, Pages 61-73, 2003
https://pubmed.ncbi.nlm.nih.gov/12901598/
The Role of Adjuvants in the Efficacy of a Peptide vaccine for Myasthenia Gravis
McAnally, James L. , Likang Xu, Matteo Villain and J.Edwin Blalock
Exp Biol Med Vo. 226(4): 307-311, 2001
https://doi.org/10.1177/153537020122600407
Prevention and Reversal of Experimental Autoimmune Myasthenia Gravis by a Monoclonal Antibody against Acetylcholine Receptor-Specific T Cells
Xu, L., M. Villain, F.S. Galin, S. Araga, and J.E. Blalock.
Cellular Immunology 208, 107-114, 2001
http://dx.doi.org/10.1006/cimm.2001.1777
A peptide vaccine that prevents experimental autoimmune myasthenia gravis by specifically blocking T cell help
Araga, Shigeru , Likang Xu, Kenji Nakashima, Matteo Villain and J. Edwin Blalock
FASEB J. 14: 185-196, 2000
http://www.fasebj.org/cgi/reprint/14/1/185.pdf
Prevention of Experimental Autoimmune Myasthenia Gravis by a Monoclonal Antibody to a Complementary Peptide for the Main Immunogenic Region of the Acetylcholine Receptor
Araga, S., F.S. Galin, M. Kishimoto, A. Adachi, and J.E. Blalock.
The Journal of Immunology, 157: 386-392, 1996
http://www.jimmunol.org/cgi/reprint/157/1/386.pdf
Use of Complementary Peptides and Their Antibodies in B-Cell-Mediated Autoimmune Disease: Prevention of Experimental Autoimmune Myasthenia Gravis with a Peptide Vaccine
Araga, S. and J.E. Blalock.
IMMUNOMETHODS 5, 130-135, 1994
http://dx.doi.org/10.1006/immu.1994.1047
Prevention of experimental autoimmune myasthenia gravis by manipulation of the immune network with a complementary peptide for the acetylcholine receptor
Araga, S., R.D. LeBoeuf and J.E. Blalock.
Proc. Natl. Acad. Sci. USA Vol. 90 Immunology, 8747-8751, 1993
http://www.pnas.org/cgi/content/abstract/90/18/8747
Complementary peptide vaccine in Multiple Sclerosis (MS)
An IgM anti-MBP Ab in the case of Waldenstrom’s macroglobulinemia with polyneuropathy expressing an idiotype reactive with an MBP epitope immunodominant in MS and EAE
Brett D. Noerager, Takashi Inuzuka, Jun-ichi Kira, J.Edwin Blalock, John N. Whitaker, F.Shawn Galin.
Journal of Neuroimmunology 113, 163-169, 2001
http://www.journals.elsevierhealth.com/periodicals/jni/article/PIIS0165572800004252/abstract
Highly related immunoglobulin light chain sequences in different multiple sclerosis patients
J.Edwin Blalock, Shan-Ren Zhou, Curtis C Maier, F.Shawn Galin, John N Whitaker.
Journal of Neuroimmunology 100, 98-101, 1999
http://www.ncbi.nlm.nih.gov/pubmed/10695719
Active immunization with complementary peptide PBM 9-1: Preliminary evidence that it modululates experimental allergic encephalomyelitis in PL/J Mice and Lewis Rats
Zhou S-R, Whitaker JN.
J. Neurosci. Res. 45, 439–446, 1996
http://www.ncbi.nlm.nih.gov/pubmed/10695719
Specific modulation of T-cells and murine experimental allergic encephalomyelitis by monoclonal anti-idiotypic antibodies
Zhou S-R, Whitaker JN.
J. Immunol. 150, 1629–1642, 1993
http://www.jimmunol.org/cgi/content/abstract/150/4/1629
Complementary peptide vaccine in Guillain-Barré Syndrome (GBS)
A complementary Peptite Vaccine That Induces T Cell Anergy and Prevents Experimental Allergic Neuritis in Lewis Rats
Araga, Shigeru, Masahiro Kishimoto, Sotoko Doi and Kenji Nakashima
Journal of Immunology, 163: 476-482, 1999